XOMA Royalty’s (XOMA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of XOMA Royalty (NASDAQ:XOMA) in a report issued on Friday,Benzinga reports. The firm currently has a $97.00 price objective on the biotechnology company’s stock.

Several other analysts have also commented on XOMA. Zacks Research lowered shares of XOMA Royalty from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 10th. Stifel Nicolaus set a $50.00 target price on shares of XOMA Royalty in a research report on Friday, December 12th. UBS Group set a $76.00 price target on shares of XOMA Royalty in a research note on Tuesday, December 9th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of XOMA Royalty in a report on Monday, December 29th. Finally, Benchmark reiterated a “buy” rating on shares of XOMA Royalty in a research note on Friday, December 12th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $61.60.

XOMA Royalty Price Performance

Shares of NASDAQ:XOMA opened at $28.71 on Friday. The company has a current ratio of 3.37, a quick ratio of 3.37 and a debt-to-equity ratio of 1.15. The stock’s fifty day simple moving average is $26.09 and its two-hundred day simple moving average is $30.39. XOMA Royalty has a 1-year low of $18.35 and a 1-year high of $39.92. The stock has a market cap of $341.94 million, a PE ratio of 19.66 and a beta of 0.86.

XOMA Royalty (NASDAQ:XOMA) last posted its earnings results on Wednesday, March 18th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.16. The firm had revenue of $13.76 million during the quarter, compared to analyst estimates of $11.13 million. XOMA Royalty had a net margin of 45.75% and a return on equity of 10.32%. As a group, analysts forecast that XOMA Royalty will post -1.41 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in XOMA. Woodline Partners LP boosted its stake in shares of XOMA Royalty by 7.9% during the first quarter. Woodline Partners LP now owns 168,550 shares of the biotechnology company’s stock valued at $3,359,000 after purchasing an additional 12,284 shares during the period. Geode Capital Management LLC boosted its position in XOMA Royalty by 9.1% during the 2nd quarter. Geode Capital Management LLC now owns 203,601 shares of the biotechnology company’s stock valued at $5,132,000 after buying an additional 16,929 shares during the period. JPMorgan Chase & Co. boosted its position in XOMA Royalty by 13.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock valued at $112,000 after buying an additional 543 shares during the period. Rhumbline Advisers grew its holdings in XOMA Royalty by 18.0% in the 2nd quarter. Rhumbline Advisers now owns 13,249 shares of the biotechnology company’s stock worth $334,000 after acquiring an additional 2,019 shares during the last quarter. Finally, Panagora Asset Management Inc. bought a new stake in XOMA Royalty in the 2nd quarter worth $463,000. 95.92% of the stock is owned by hedge funds and other institutional investors.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.